0001062993-16-012532.txt : 20161129 0001062993-16-012532.hdr.sgml : 20161129 20161129171511 ACCESSION NUMBER: 0001062993-16-012532 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161128 FILED AS OF DATE: 20161129 DATE AS OF CHANGE: 20161129 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSPECIFICS TECHNOLOGIES CORP CENTRAL INDEX KEY: 0000875622 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 113054851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 35 WILBUR ST CITY: LYNBROOK STATE: NY ZIP: 11563 BUSINESS PHONE: 5165937000 MAIL ADDRESS: STREET 1: 35 WILBUR STREET CITY: LYNBROOK STATE: NY ZIP: 11563 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wegman Thomas CENTRAL INDEX KEY: 0001355189 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34236 FILM NUMBER: 162023482 MAIL ADDRESS: STREET 1: 1764 BRIAR PLACE CITY: MERRICK STATE: NY ZIP: 11566 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2016-11-28 0000875622 BIOSPECIFICS TECHNOLOGIES CORP BSTC 0001355189 Wegman Thomas C/O BIOSPECIFICS TECHNOLOGIES CORP. 35 WILBUR STREET LYNBROOK NY 11563 1 1 1 0 President Common Stock, $.001 par value 2016-11-28 4 S 0 11055 48.0369 D 964824 D Common Stock, $.001 par value 2016-11-29 4 S 0 8945 48.3161 D 955879 D The selling price of $48.0369 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $47.50 to $49.40. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. The selling price of $48.3161 is reflective of the weighted average sale price of all transactions reported on this line. The prices for the transactions reported on this line range from $48.25 to $48.77. The reporting person undertakes to provide, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price. /s/ Carl A. Valenstein, attorney-in-fact for Thomas Wegman 2016-11-29